NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: Inhibition with iloprost

European Journal of Pharmacology

Volumn 658, Issue 2-3, 2011, Pages 187-192

  Muzaffar, Saima ^a   Shukla, Nilima ^a   Massey, Yolanda ^a   Angelini, Gianni D ^a   Jeremy, Jamie Y ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Human vascular smooth muscle cells; NADPH oxidase; Prostacyclin; Thromboxane A2 synthase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 8 ISOPROSTANE F2 ALPHA; APOCYNIN; ILOPROST; PICOTAMIDE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; THROMBOXANE A2; THROMBOXANE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ACETOPHENONES; GENE SILENCING; HUMANS; ILOPROST; MUSCLE, SMOOTH, VASCULAR; NADH, NADPH OXIDOREDUCTASES; RNA, SMALL INTERFERING; THROMBOXANE-A SYNTHASE; UP-REGULATION;

EID: 79953768903     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.02.020     Document Type: Article

References (40)

1. -/- mice. J. Clin. Invest. 108, 1513-1522.
2. Bedard, K., Krause, K.H., 2007. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87, 245-313.
3. Bloor, J., Shukla, N., Smith, F.C.T., Angelini, G.D., Jeremy, J.Y., 2010. Folic acid administration reduces neointimal thickening, augments neo vasa vasorum formation and reduces oxidative stress in saphenous vein grafts fromdiabetic pigs. Diabetologia 53, 980-988.
4. Celestini, A., Violi, F., 2007. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc. Health Risk Manag 3, 93-98. (Pubitemid 46860720)
5. Egan, K.M., Wang, M., Fries, S., Lucitt, M.B., Zukas, A.M., Puré, E., Lawson, J.A., FitzGerald, G.A., 2005. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111, 334-342. (Pubitemid 40165341)
6. Funk, C.D., FitzGerald, G,.A., 2007. COX-2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol. 50, 470-479.
7. Gao, L., Mann, G.E., 2009. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signaling. Cardiovasc. Res. 82, 9-20.
8. 2 production in Type 1 diabetic patients: a double blind cross over trial. Diabetes 37, 262-264.
9. 2 and prostacyclin. Adv. Cyclic Nucleotide Res. 9, 597-609.
10. Gryglewski, R.J., 2008. Prostacyclin among prostanoids. Pharmacol. Rep. 60, 3-11.
11. Hilenski, L.L., Clempus, R.E., Quinn, M.T., Lambeth, J.D., Griendling, K.K., 2004. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24, 677-683.
12. Jeremy, J.Y., Mikhailidis, D.P., Dandona, P., 1988. Excitatory receptor-linked prostanoid synthesis in mammalian smooth muscle: role of calcium, protein kinases & G proteins. Prostagl. Leuk. Ess. Fatty Acids Revs 34, 215-228.
13. Jeremy, J.Y., Jackson, C.L., Bryan, A.J., Angelini, G.D., 1996. Eicosanoids, fatty acids and restenosis following balloon angioplasty and vein graft surgery. Prostagl. Leukotr. Ess. Fatty Acids 54, 385-402.
14. Jeremy, J.Y., Mehta, D., Bryan, A.J., Lewis, D., Angelini, G.D., 1997. Platelets and saphenous vein graft failure following coronary artery bypass graft surgery. Platelets 8, 295-309. (Pubitemid 27485402)
15. Jeremy, J.Y., Rowe, D., Emsley, A.M., Newby, A.C., 1999. Nitric oxide and vascular smooth muscle cell proliferation. Cardiovasc. Res. 43, 580-594.
16. Jeremy, J.Y., Angelini, G.D., Khan, M., Morgan, R.J., Thompson, C.S., Bruckdorfer, K.R., Naseem, K.M., 2000. Platelets, oxidant stress anderectile dysfunction: anhypothesis. Cardiovasc. Res. 46, 50-54.
17. Jeremy, J.Y., Yim, A.P., Wan, S., Angelini, G.D., 2002. Oxidative stress, nitric oxide and vascular disease. Cardiovasc. Surg. 17, 324-327.
18. Jeremy, J.Y., Shukla, N., Muzaffar, S., Angelini, G.D., 2004. Reactive oxygen species, vascular disease and cardiovascular surgery. Curr. Vasc. Pharmacol. 2, 229-236.
19. Jeremy, J.Y., Muzaffar, S., Mill, C., Shukla, N., 2010. In: Sarah, George, Jason, Johnson (Eds.), Atherosclerosis: Molecular and Cellular Mechanisms Elsevier (pub), pp. 257-271.
20. Kenneth, N.S., Rocha, S., 2008. Regulation of gene expression by hypoxia. Biochem. J. 414, 19-29.
21. Lee, M.Y., San Martin, A.S., Mehta, P.K., Dikalova, A.E., Garrido, A.M., Datla, S.R., Lyons, E., Krause, K.H., Banfi, B., Lambeth, J.D., Lassègue, B., Griendling, K.K., 2009. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1): contribution to injury-induced neointimal formation. Arterioscler. Thrombos. Vasc. Biol 29, 480-486.
22. McKellar, G.E., McCarey, D.W., Sattar, N., McInnes, I.B., 2009. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat. Rev. Cardiol. 6, 410-417.
23. 2 and prostacyclin. Pharmacol. Rev. 30, 293-331.
24. Morrow, J.D., 2005. Identification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thrombos. Vasc. Biol 25, 279-283.
25. Muzaffar, S., Jeremy, J.Y., Stuart-Smith, K., Angelini, G.D., Shukla, N., 2003. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 58, 598-604. (Pubitemid 36808131)
26. 2α in cultured porcine pulmonary artery vascular smooth muscle cells. Br. J. Pharmacol. 141, 488-496.
27. Muzaffar, S., Shukla, N., Angelini, G.D., Jeremy, J.Y., 2004b. Nitroaspirins and SIN-1, but not aspirin, inhibit the expression of endotoxin- and cytokine-induced NADPH oxidase in vascular smooth muscle cells from pig pulmonary arteries. Circulation 110, 1140-1147. (Pubitemid 39319015)
28. phox expression in porcine pulmonary endothelial cells through a cyclic GMP dependent mechanism. Br. J. Pharmacol. 146, 109-117.
29. Muzaffar, S., Shukla, N., Jeremy, J.Y., 2005b. NADPH oxidase: a promiscuous therapeutic target for cardiovascular drugs? Trends Cardiovasc Med 15, 278-282.
30. phox and endothelial nitric oxide synthase in the pulmonary artery. Thorax 60, 305-313.
31. Muzaffar, S., Shukla, N., Angelini, G.D., Jeremy, J.Y., 2006. Superoxide auto-augments superoxide formation in isolated porcine pulmonary artery endothelial cells through upregulation of NADPH oxidase expression: inhibitionwith iloprost. Eur. J. Pharmacol. 538, 108-114.
32. Muzaffar, S., Shukla, N., Jeremy, J.Y., 2008a. Acute inhibition of superoxide formation and Rac(1) activation by nitric oxide and iloprost in human vascular smooth muscle cells in response to the thromboxane A(2) analogue, U46619. Prostagl. Leukot. Essent. Fatty Acids 78, 247-255.
33. Muzaffar, S., Shukla, N., Bond, M., Jeremy, J.Y., 2008b. Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular smooth muscle cells: inhibition with iloprost and NONOate. Br. J. Pharmacol. 2008 (155), 847-856.
34. 2: physiology/ pathophysiology, cellular signal transduction and pharmacology. Pharm. Ther 118, 18-35.
35. 2 from prostaglandin endoperoxides. Nature 261, 558-560.
36. Shukla, N., Greaves, N.S., Angelini, G.D., Jeremy, J.Y., 2008. Folic acid reduces intravascular oxidative stress in diabetic rabbits. Metabolism 57, 774-781. (Pubitemid 351697908)
37. Stefanski, J., Pawliczak, D., 2008. Apocynin: molecular aptitudes. Med Inflamm: Article ID 106507.
38. Vendrov, A.E., Hakim, Z.S., Madamanchi, N.R., Rojas, M., Madamanchi, C., Runge, M.S., 2007. Atherosclerosis is attenuated by limiting superoxide generation in bothmacrophages and vessel wall cells. Arterioscler. Thrombos. Vasc. Biol 27, 2714-2720.
39. 2 receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51, 198-203.
40. Zuccullo, A., Shi, C., Mastroianni, R., Maitland-Toolan, K.A., Weisbrod, R.M., Zang, M., Xu, S., Jiang, B., Oliver-Krasinski, J.M., Cayatte, A.J., Corda, S., Lavielle, G., Verbeuren, T.J., Cohen, R.A., 2005. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112, 3001-3008. (Pubitemid 41612304)